Previous Close | 0.6000 |
Open | 0.6000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 1.00 |
Expire Date | 2024-07-19 |
Day's Range | 0.4500 - 0.6000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.